Boston Scientific Receives FDA Approval For The POLARx Cryoablation System
Portfolio Pulse from Happy Mohamed
Boston Scientific Corporation (NYSE:BSX) has received FDA approval for its POLARx Cryoablation System, a device for treating patients with paroxysmal atrial fibrillation. The system features a unique catheter that can adjust to two balloon sizes, allowing physicians to better tailor care for individual patients. The system has demonstrated safety and effectiveness in clinical trials, with a primary event-free rate of 96.0% at 12 months.
August 08, 2023 | 9:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Boston Scientific's new FDA-approved POLARx Cryoablation System could potentially boost the company's market share in the atrial fibrillation treatment market. The device's unique features and proven effectiveness may attract more physicians and patients.
The FDA approval of Boston Scientific's POLARx Cryoablation System is a significant milestone for the company. It not only validates the safety and effectiveness of the device but also opens up a large market of patients with atrial fibrillation. The unique features of the device, such as the adjustable balloon sizes, could make it more appealing to physicians and patients, potentially leading to increased sales and a positive impact on the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100